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Abstract
Chromosome 15q24 microdeletion syndrome is a recently described rare microdeletion syndrome that has been
reported in 19 individuals. It is characterized by growth retardation, intellectual disability, and distinct facial features
including long face with high anterior hairline, hypertelorism, epicanthal folds, downslanting palpebral fissures, sparse
and broad medial eyebrows, broad and/or depressed nasal bridge, small mouth, long smooth philtrum, and full lower
lip. Other common findings include skeletal and digital abnormalities, genital abnormalities in males, hypotonia,
behavior problems, recurrent infections, and eye problems. Other less frequent findings include hearing loss, growth
hormone deficiency, hernias, and obesity. Congenital malformations, while rare, can be severe and include structural
brain anomalies, cardiovascular malformations, congenital diaphragmatic hernia, intestinal atresia, imperforate anus, and
myelomeningocele. Karyotypes are typically normal, and the deletions were detected in these individuals by array
comparative genomic hybridization (aCGH). The deletions range in size from 1.7-6.1 Mb and usually result from
nonallelic homologous recombination (NAHR) between paralogous low-copy repeats (LCRs). The majority of 15q24
deletions have breakpoints that localize to one of five LCR clusters labeled LCR15q24A, -B, -C, -D, and -E. The smallest
region of overlap (SRO) spans a 1.2 Mb region between LCR15q24B to LCR15q24C. There are several candidate genes
within the SRO, including CYP11A1, SEMA7A, CPLX3, ARID3B, STRA6, SIN3A and CSK, that may predispose to many of the
clinical features observed in individuals with 15q24 deletion syndrome. The deletion occurred as a de novo event in all
of the individuals when parents were available for testing. Parental aCGH and/or FISH studies are recommended to
provide accurate genetic counseling and guidance regarding prognosis, recurrence risk, and reproductive options.
Management involves a multi-disciplinary approach to care with the primary care physician and clinical geneticist
playing a crucial role in providing appropriate screening, surveillance, and care for individuals with this syndrome. At
the time of diagnosis, individuals should receive baseline echocardiograms, audiologic, ophthalmologic, and
developmental assessments. Growth and feeding should be closely monitored. Other specialists that may be involved
in the care of individuals with 15q24 deletion syndrome include immunology, endocrine, orthopedics, neurology, and
urology. Chromosome 15q24 microdeletion syndrome should be differentiated from other genetic syndromes,
particularly velo-cardio-facial syndrome (22q11.2 deletion syndrome), Prader-Willi syndrome, and Noonan syndrome.
These conditions share some phenotypic similarity to 15q24 deletion syndrome yet have characteristic features specific
to each of them that allows the clinician to distinguish between them. Molecular genetic testing and/or aCGH will be
able to diagnose these conditions in the majority of individuals.
Disease name and synonyms: Chromosome 15q24 deletion syndrome
15q24 deletion syndrome
15q24 microdeletion syndrome
Definition and diagnostic criteria
Chromosome 15q24 microdeletion syndrome is a rare
and novel microdeletion syndrome characterized by pre-
and post-natal growth retardation, intellectual disability,
distinct facial features, and genital, skeletal, and digital
anomalies. Additional common features include hypoto-
nia, behavioral problems, and recurrent infections (table
1) [1-10]. Although some of the characteristic features
may be non-specific, the combination of these findings
should prompt the clinician to suspect this diagnosis.
Most of the deletions are between 1.7 to 6.1 megabases
(Mb) in size, with the smallest region of overlap (SRO)
spanning a 1.2 Mb region (Figure 1) [1-10]. Routine
high-resolution karyotypes typically do not detect the
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drome were diagnosed by using array comparative geno-
mic hybridization (CGH) [1-10].
Epidemiology
The incidence of 15q24 deletion syndrome is unknown.
To date, there have been 19 published reports of indivi-
duals with 15q24 deletion syndrome in which clinical
information and detailed mapping of the genomic break-
points are available [1-10]. The first case was reported in
2007 by Sharp et al [1]. Prior to this time, the wide-
spread use of array CGH was limited, therefore the diag-
nosis may have gone undetected and undiagnosed. With
the advent of array CGH, we anticipate that the present
number of reported cases represents an underestimate
of the actual prevalence of the disorder. A recent study
by Cooper et al [11] reviewed 15,767 cases with intellec-
tual disability and various congenital defects referred to
their laboratory for array CGH. They identified 15q24
deletion in nine patients with intellectual disability, for
an incidence of approximately 1 in 1751 in this popula-
tion. This would make it approximately 1/10
th as fre-
quent as 22q11.2 deletion syndrome which was
identified in 96 cases with intellectual disability (~1 in
164). Given these estimates, and the proposed incidence
of 22q11.2 deletion syndrome, the overall incidence of
15q24 microdeletion in the general population may
approach approximately 1 in 42,000. We would expect
the deletion to occur with equal frequency in males and
females; however 16 of the 19 reported cases (84%) are
m a l e s .T h er e a s o nf o rt h ed i s c r e p a n c yi nt h em a l et o
female sex ratio of 15q24 deletion is not clearly under-
stood and may just be representative of the small sam-
ple size of cases and ascertainment bias, rather than a
true phenomenon. The deletion occurred as a de novo
event in the 18 individuals that the parents were tested
[1-10].
Clinical description
The clinical characteristics of 15q24 deletion syndrome
are based on the clinical features reported in the 19
patients with 15q24 microdeletion and presented in
Table 1[1-10]. At birth, approximately one-third of the
individuals had low birth weight consistent with intrau-
terine growth retardation. Feeding difficulties and failure
to thrive were reported in approximately 20%. However,
in later childhood, growth parameters were extremely
variable with nearly 30% of individuals still exhibiting
postnatal growth retardation and short stature, while
17% had obesity. Additionally, almost 20% of individuals
were reported to have microcephaly. Two individuals
with 15q24 deletion had documented growth hormone
(GH) deficiency. This might be an underascertainment
of the actual prevalence of GH deficiency in this
Figure 1 Schematic diagram showing approximate size, position (NCBI36/hg18 assembly), gene, and breakpoint locations of reported
cases of 15q24 microdeletions (upper section) and 15q24 microduplications (lower section). Reference and case number are located in
the boxes to the left of the diagram. Genes within the SRO are indicated below the diagram.
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individuals.
Growth delay, feeding difficulties, and distinct facial
features were often the presenting early symptoms of
15q24 deletion syndrome. Distinct facial features,
including long face with high anterior hairline, epi-
canthal folds, hypertelorism, downslanting palpebral fis-
sures, sparse and broad medial eyebrows, broad and/or
depressed nasal bridge, long smooth philtrum, and small
mouth with full lower lip were common in all indivi-
duals. Ear abnormalities were variable, but present in
nearly two-thirds of individuals and included large ears,
ear lobe pits, anteverted ear lobes, and protuberant ears.
These features may be subtle in the newborn period,
but may become more evident with age.
All of the individuals have developmental delay of
varying degrees, usually in the range of mild to moder-
ate intellectual disability. In reviewing the literature, 6/
19 cases were classified as having mild intellectual dis-
ability, 2/19 were classified as moderate, 1/19 was classi-
fied as moderate-to-severe, 3/19 were classified as
severe, and the remaining 7/17 were not further charac-
terized based on severity. Behavior abnormalities, such
as autism, hyperactivity, aggression, and attention deficit
disorder have been reported in 37% individuals with
15q24 deletion syndrome. McInnes et al performed tar-
geted aCGH across the 15q24 region on ~1500 indivi-
duals with autism spectrum disorders and identified a
de novo atypical deletion of 3.06 Mb in 15q23-q24.1 in a
5 year old male with autism [8]. In addition to autism,
he exhibited other characteristic features of 15q24 dele-
tion syndrome including, moderate intellectual disability,
low birth weight, distinct facial features, 2,3 toe syndac-
tyly, mild scoliosis, and recurrent respiratory infections.
Autism or autistic-like features were reported in three
additional individuals with 15q24 deletion [1,9,10].
Skeletal and digital deformities have been described in
the majority of individuals. Digit abnormalities such as
proximally implanted and/or hypoplastic thumbs, clino-
dactyly, brachydactyly, overriding toes, toe syndactyly,
and small hands were found in approximately 90% of
Table 1 Summary of clinical manifestation in patients
with 15q24 microdeletion syndrome
Characteristic Cases
Gender Male - 16/19 (84%)
De novo occurrence 18/18 (100%)
Developmental delay 19/19 (100%)
Growth abnormalities 10/18 (56%)
Low birth weight/IUGR 6/18 (33%)
Short stature 5/18 (28%)
Obesity 3/18 (17%)
Microcephaly 3/18 (17%)
Feeding difficulties 4/18 (22%)
Distinct Facial features 19/19 (100%)
Long face 6/18 (33%)
Facial asymmetry 5/18 (28%)
High anterior hairline 12/18 (67%)
Epicanthal folds 9/18 (50%)
Hypertelorism 8/18 (44%)
Downslanting palpebral fissures 9/18 (50%)
Sparse, broad medial eyebrows 9/18 (50%)
Strabismus 7/18 (39%)
Nystagmus 2/18 (11%)
Broad nasal base 6/18 (33%)
Depressed nasal bridge 5/18 (28%)
High nasal bridge 2/18 (11%)
Ear abnormalities 11/18 (61%)
Palate abnormalities 4/18 (22%)
Long smooth philtrum 10/18 (56%)
Full lower lip 7/18 (39%)
Small mouth 6/18 (33%)
Genital abnormalities 11/18 (61%)
Hypospadias 6/15 (40%)
Microphallus 5/15 (33%)
Cryptorchidism 3/15 (20%)
Digit abnormalities 16/18 (89%)
Thumb abnormalities 7/18 (39%)
Brachydactyly/short digits 6/18 (33%)
Clinodactyly 3/18 (20%)
Toe abnormalities 6/18 (33%)
Skeletal abnormalities 11/18 (61%)
Joint laxity 10/18 (56%)
Scoliosis/kyphosis 6/18 (33%)
Neurologic findings 15/19 (79%)
Hypotonia 11/18 (61%)
Behavior problems 7/19 (37%)
MRI abnormalities 8/18 (44%)
Other features
Recurrent infections 7/18 (39%)
Hernias 5/19 (26%)
Table 1 Summary of clinical manifestation in patients
with 15q24 microdeletion syndrome (Continued)
Congenital heart disease 4/18 (22%)
Hearing loss 4/18 (22%)
Diaphragmatic hernia 2/18 (11%)
Intestinal atresia 2/18 (11%)
Imperforate anus 1/18 (6%)
Coloboma 1/18 (6%)
Dental problems 1/18 (6%)
Myelomeningocele 1/18 (6%)
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viduals were reported to have joint laxity and scoliosis.
Some individuals were reported to have hernias which,
in addition to the joint laxity, suggest that there may be
an underlying connective tissue abnormality in indivi-
duals with 15q24 deletion syndrome [3].
Hypotonia has been reported in 60% of individuals
with 15q24 deletion syndrome. Approximately half of
the individuals had abnormal brain imaging on magnetic
resonance imaging (MRI). The features in those with
abnormalities are variable and include: dysplastic or
abnormal corpus callosum, cortical atrophy, focal corti-
cal dysplasia, and hypoplastic olfactory bulbs. The inci-
dence of seizure activity is relatively low with only one
individual having reported seizures [1].
Genital abnormalities are reported in a majority of
individuals (60%) and include hypospadias, microphallus,
and cryptorchidism. These findings, in addition to other
possible malformations or dysmorphisms in the new-
born period, may prompt an earlier genetics evaluation
and diagnosis when compared to females who have not
been reported to have urogenital anomalies. This may
possibly explain why the majority of reported patients
are males.
Nearly 40% of individuals with 15q24 deletion syn-
drome had a history of recurrent infections, such as
chest, upper airway, and ear infections. The etiology of
the recurrent infections is currently unknown. Immuno-
deficiency could be the underlying cause; however,
immunologic work up has not been reported in any of
those individuals. Recurrent ear infections may be one
of the factors that predispose to hearing loss which has
been formally evaluated and diagnosed in nearly 25% of
individuals with 15q24 deletion syndrome.
Birth defects have been reported in several individuals
including congenital heart defects (such as tetralogy of
Fallot and ventricular septal defects) in four (~20%),
intestinal atresia in two, imperforate anus in one [5], iris
coloboma in one, myelomeningocele in one, and dia-
phragmatic hernia in two individuals. Other features
that have been reported in a minority of cases include
strabismus [1-3,6,10] nystagmus [1,5,8] and dental
abnormalities [1].
One individual with 15q24 deletion syndrome was
reported to have acute lymphoblastic leukemia [4] and
another individual was diagnosed with cardiac rhabdo-
myoma [7]. No additional malignancies or tumors have
been reported in this population, therefore it is currently
unknown if there is a predisposition to tumors and neo-
plasia in individuals with 15q24 deletion syndrome.
Two individuals with 15q24 deletion syndrome had
another concurrent chromosome abnormality [7,9].
These individuals exhibited additional clinical features
with a more severe phenotype than that observed in
previously reported patients with isolated 15q24 rearran-
gements and it was suggested that the number of geno-
mic rearrangements (genomic mutational load) may
contribute to the phenotypic severity and variability in
patients with 15q24 deletions [7,12,13].
Etiology
15q24 deletion syndrome is a microdeletion syndrome
resulting from the interstitial loss of 15q24 ranging in
size from ~1.7 to 6.1 Mb. All but one case share the
smallest region of overlap (SRO) of ~1.2 Mb in size (see
Figure 1) [1-10]. The 15q24 deletions are primarily
mediated by nonallelic homologous recombination
(NAHR) between paralogous low-copy repeats (LCRs).
The majority of 15q24 deletions have breakpoints that
localize to LCR clusters. Five LCR clusters have been
identified, labeled, LCR15q24A, LCR15q24B,
LCR15q24C, LCR15q24D, and LCR15q24E. The SRO
spans the 1.2 Mb region between LCR15q24B to
LCR15q24C. Some patients have had breakpoints that
do not lie within the LCR regions. Breakpoint sequen-
cing for the 15q24 deletion in one of those patients
revealed microhomology suggesting that other possible
mechanisms include nonhomologous end joining
(NHEJ) and fork stalling and template switching
(FoSTeS)/microhomology-mediate break-induced repli-
cation (MMBIR) [7,14-17].
The SRO is a gene-rich region that includes several
genes including: CYP11A1, SEMA7A, CPLX3, ARID3B,
STRA6, SIN3A and CSK. CYP11A1 encodes the choles-
terol side-chain cleavage enzyme and it has been sug-
gested that haploinsufficiency of CYP11A1 may
contribute to the genital abnormalities in patients with
15q24 deletion syndrome [7]. SEMA7A and CPLX3 are
two genes that may play an important role in brain
development and may contribute to the cognitive dis-
ability in individuals with this deletion [7]. Haploinsuffi-
ciency of ARID3B and STRA6 may contribute to the
congenital malformations observed in a handful of
patients with 15q24 deletion syndrome. The ARID3B
gene is involved with transcription regulation in
embryonic development. Homozygous null mutations in
the ARID3B mouse model predispose to an increased
incidence of cardiovascular malformations [18]. Simi-
larly, homozygous loss-of-function mutations in STRA6
have also been associated with cardiovascular malforma-
tions, microphthalmia, and diaphragmatic hernias
[19,20]. SIN3A and CSK both play roles in tumor sup-
pression and their deletion may lead to an increased
predisposition to and risk of neoplasia in this patient
population [7].
Apparent reciprocal 15q24 duplications involving the
SRO have been reported in 4 individuals [4,7,21]. Two
of these individuals shared multiple clinical features
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tonia, joint limitations, digital abnormalities, and distinct
facial features such as down-slanting palpebral fissures,
epicanthal folds, smooth philtrum, and full lower lip
[4,21]. However, other reported individuals with the
reciprocal 15q24 duplication did not have the same clin-
ical phenotype, therefore, it is unclear whether 15q24
duplications result in a distinct clinical phenotype [7,21].
Diagnostic methods
Oligonucleotide array CGH with confirmation by fluor-
escent in-situ hybridization (FISH) detects most, if not
all, deletions of 15q24. Routine high-resolution chromo-
some analysis, when performed, is typically normal.
Array CGH will also be able to detect additional chro-
mosome copy number variants (CNVs) that may influ-
ence the clinical phenotype. Parental FISH and/or
aCGH should be offered to the parents when 15q24
deletion is detected in a child.
Differential diagnoses
15q24 deletion syndrome should be differentiated from
other microdeletion/duplication and genetic syndromes
that have similar presentations. Individuals with 22q11.2
deletion syndrome (velo-cardio-facial syndrome) can
have distinct facial features, asymmetric facies, and
developmental delay. However, congenital heart defects
and palate abnormalities are much more common in
22q11.2 deletion syndrome than in 15q24 deletion syn-
drome. Array CGH or FISH for 22q11.2 deletion will
detect this deletion.
There is also significant overlap between the features
of 15q24 deletion syndrome and Prader-Willi syndrome
(PWS). Prader-Willi syndrome, a genetic condition
caused by loss of the paternal copy of 15q11.2, is char-
acterized by neonatal hypotonia, feeding difficulties, and
genital abnormalities, such as hypogonadism. In addi-
tion, individuals with PWS will typically have mild to
moderate intellectual disability, behavior problems, and
obesity. The degree of hypotonia and feeding difficulties
is more severe in individuals with PWS than what
would be expected in newborns with 15q24 deletion
syndrome. In addition, obesity in older children with
PWS is much more common than what has been
reported in individuals with 15q24 deletion. Array CGH,
FISH for PWS and/or methylation studies for PWS will
detect the majority of cases of Prader-Willi syndrome.
Individuals with Noonan syndrome may share some
similarities to individuals with 15q24 deletion syndrome,
particularly, distinct facial features, skeletal abnormal-
ities, short stature, cryptorchidsm, failure to thrive, and
developmental delay. However the facial features of indi-
viduals with Noonan syndrome are more characteristic,
whereas the facial features of individuals with 15q24
deletion may be rather subtle, especially in the newborn
period. Failure to thrive and feeding difficulties, while
common in both conditions, tends to be more severe in
Noonan syndrome. Both conditions have a high inci-
dence of skeletal malformations; however pectus defor-
mities are more common in Noonan syndrome, whereas
digit abnormalities are predominant in 15q24 deletion
syndrome. Molecular sequencing of genes in Ras-MAPK
(mitogen-activated protein kinase) pathway will diagnose
Noonan syndrome (and related conditions) in the
majority of cases.
Genetic counseling
Variable expressivity exists between individuals with
15q24 deletion syndrome. Some of the variability may
be attributed to the specif i cs i z ea n dl o c a t i o no ft h e
deletion, however, even individuals with similar break-
points exhibit diverse phenotypes. Offering accurate
anticipatory guidance and counseling for individuals
with 15q24 deletion syndrome can be challenging espe-
cially if the individual has additional genomic rearrange-
ments that may predispose to other clinical
consequences. This may interfere with the clinicians’
ability to provide an accurate assessment or outcome in
the child. The phenotype, clinical features, and prog-
nosis will depend on the size, location, and genes
involved in the additional chromosome abnormality.
The combination of the additional rearrangements
w i t ht h e1 5 q 2 4d e l e t i o nm a yh a v ea na d d i t i v ee f f e c ta s
the presence of multiple genomic rearrangement in an
individual (the genomic mutational load) can result in
more severe phenotype and additional features that are
not typically observed in individuals carrying single rear-
rangements [7,12,13,22]. Genetic counseling should take
into account this potential effect and be attentive to
additional phenotypic variability that may occur.
To date, all of the cases where parents were available
for testing (18 out of 19 cases) indicated that the dele-
tion occurred as a de novo event in the child. However,
for genetic counseling, reproductive planning, and
anticipatory guidance, it is recommended that both par-
ents have FISH or aCGH testing in order to confirm
that neither parent also carries the deletion. This is par-
ticularly important if the individual has an additional
chromosome abnormality or imbalance that may have
been inherited from a balanced rearrangement in one of
the parents.
Individuals with 15q24 deletion syndrome have a 50%
chance of passing on the deletion to their offspring. To
date, although the two oldest reported individuals are 33
years old, there have not been any reported cases of
individuals with 15q24 deletion syndrome reproducing,
therefore, it is unknown if there are any fertility-related
issues in this population. Longitudinal follow-up of
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determine if the high incidence of genital abnormalities
predisposes to fertility issues later in life.
Antenatal diagnosis
Deletion of 15q24 can be detected in amniotic fluid or
chorionic villi samples. Since routine karyotyping is not
typically sufficient to detect the deletion, aCGH should
be offered to parents who carry a structural rearrange-
ment that may predispose to 15q24 deletion or if fetal
abnormalities are noted antenatally. Prenatal ultrasono-
graphy may detect some cardiovascular malformations,
diaphragmatic hernias, and growth retardation in the
fetus with 15q24 deletion, however, the most character-
istic features of the condition, specifically distinct facial
features and digit abnormalities, may be difficult to
detect.
Management
The proposed management recommendations are based
o nt h ec u r r e n tk n o w l e d g eo ft h es m a l ln u m b e ro f
patients reported with this condition in conjunction
with the authors’ clinical experience, and are meant to
serve as a guideline for treating individuals with this
condition.
Routine medical management of individuals with
15q24 deletion syndrome and coordination of referrals
can be performed by the individual’s primary care physi-
cian, however most individuals will require multidisci-
plinary care from a variety of subspecialists (Table 2).
Initial presenting features may include failure to thrive,
feeding difficulties, hypotonia, genital anomalies, and
distinct facial features. Referral to a clinical geneticist is
indicated in any child with a combination of these
findings. Detailed physical examination, medical history,
and developmental assessment should prompt genetic
testing such as aCGH, which will diagnose microdele-
tions of 15q24. Periodic evaluation by a clinical geneti-
cist is warranted to update the family on new
information or symptoms that may be related to 15q24
deletion syndrome.
Growth and Feeding
The primary care physician should closely monitor all
growth parameters in any individual diagnosed with
15q24 deletion syndrome. Referral to a gastroenterolo-
gist and/or feeding and nutrition clinic is warranted in
any infant with 15q24 deletion syndrome and feeding
difficulties, failure to thrive, or improper weight gain.
Because of the risk of childhood obesity in individuals
with 15q24 deletion syndrome, weight should be closely
monitored even in those subjects with normal growth
parameters. Nutritional counseling is recommended in
those individuals who experience excessive weight gain.
For children with growth retardation, evaluation by an
endocrinologist for GH stimulation studies is also
recommended. Although no data is available about the
effect of GH treatment in individuals with 15q24 dele-
tion, we would except that such treatment would be
helpful especially in those with documented GH
deficiency.
Development and Behavior
Given the high incidence of developmental delay, intel-
lectual disability, and behavior problems in children
with 15q24 deletion syndrome, formal neurocognitive
and behavior assessment is recommended to determine
the child’s specific learning pattern and behavioral
Table 2 Recommended clinical evaluations and management for individuals with 15q24 deletion syndrome
Specialist Evaluation at time of diagnosis Screening and surveillance
Primary care physician Initiate referrals to subspecialist, monitor growth and
development
Assess growth parameters and development at
each visit
Development clinic Neurocognitive (developmental) and behavioral evaluation At time of diagnosis, then annually in childhood
Geneticist Confirmation of diagnosis and periodic follow-up
evaluations
At time of diagnosis, then annually
Audiology Routine audiology evaluation At time of diagnosis, then as needed.
Ophthalmology Evaluate for coloboma, visual acuity, nystagmus, strabismus At time of diagnosis, then as needed.
Cardiology Echocardiogram to evaluate for congenital heart defects At time of diagnosis, then as needed
Allergy and Immunology Immune work-up for recurrent and persistent infections As needed
Endocrine Growth hormone studies for growth retardation As needed
Gastroenterology/Feeding and
Nutrition
Feeding assessment for failure to thrive and growth
retardation
As needed
Neurology Brain MRI for structural malformations and EEG for seizures As needed
Orthopedics Spine x-rays and scoliosis evaluation As needed
Urology Evaluate for genital abnormalities As needed
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this syndrome. Therefore periodic follow-up with a
developmental and/or behavioral specialist is warranted.
Early childhood intervention, encompassing physical
therapy, occupational therapy, and speech therapy is
needed in most of the cases.
Neurologic manifestations
As structural brain anomalies have been reported in
approximately half of all of cases of 15q24 deletion,
brain magnetic resonance imaging (MRI) studies are
indicated in any individual with 15q24 deletion and
abnormal neurological examination. Referral to neurol-
ogy is needed in individuals with structural brain mal-
formations or if seizures are suspected.
Cardiac manifestations
A baseline echocardiogram is recommended in any indi-
vidual with the new diagnosis of 15q24 deletion syn-
drome. Follow-up cardiology evaluations and
echocardiograms should be performed based on the
results of initial echocardiogram and at the discretion of
the patient’s cardiologist.
Ophthalmologic manifestation
Ophthalmologic abnormalities are common in indivi-
duals with 15q24 deletion syndrome; therefore, baseline
ophthalmologic evaluations are recommended to screen
for structural eye abnormalities and periodic ophthalmo-
logic evaluations should be performed to screen for nys-
tagmus and strabismus.
Orthopedic manifestations
Physical examination of the curvature of the spine needs
to be evaluated with every routine care visit. Spine x-
rays are indicated if the child shows any signs of scolio-
sis and/or kyphosis. If scoliosis and/or kyphosis develop
then referral to orthopedics is warranted for follow up
and discussing various treatment options.
Urogenital abnormalities
A majority of the males with 15q24 have genital
abnormalities. Referral to urology for evaluation of the
genital abnormalities, if present, is recommended in
order to determine if surgical correction or any other
treatment is indicated.
Recurrent infections
Individuals with 15q24 deletion syndrome are at risk for
recurrent chest, upper airway, and ear infections. To
date, documented immune deficiency has not been
reported in any individual with 15q24 deletion syn-
drome, however, a referral to immunology may be war-
ranted for recurrent and persistent infections. Referral
to otolaryngology is recommended in case of recurrent
otitis media and a low threshold is needed for placing
pressure equalization (PE) tubes in children with 15q24
deletion syndrome. Recurrent otitis media may also lead
to conductive hearing loss, which may affect a child’s
expressive and receptive language development; there-
fore, periodic audiologic evaluation is also indicated.
Prognosis
The prognosis for individuals with 15q24 deletion syn-
drome depends on the severity and extent of congenital
malformations. Major birth defects have been reported
including, tetralogy of Fallot, myelomeningocele, intest-
inal atresia, and congenital diaphragmatic hernia (CDH).
The prognosis for any individual with CDH is guarded
and related to size, location, and visceral involvement of
the diaphragmatic hernia [23]. In general, the majority
of individuals with 15q24 deletion typically do not have
life-threatening organ malformations. The natural his-
tory of 15q24 deletion syndrome is currently unknown
since there are very few children and even fewer adoles-
cents and adults reported with this deletion. The oldest
reported patients, who were 33-years-old at the time of
their report, have variable outcome [1,3]. The individual
reported by Sharp et al. is a 33-year-old male who had
mild developmental delay as a child. He has short sta-
ture and relatively mild intellectual disability with good
language skills as an adult [1]. Van Esch et al. also
reported a 33-year-old male who had severe develop-
mental delay and intellectual disability, hypotonia, and
limited speech [3]. He had hyperactive behavior with
aggressive outbursts in childhood and adolescence and
remained difficult to handle in adulthood despite psy-
chopharmacological therapy. Longitudinal follow-up of
individuals with this deletion will clarify the develop-
mental and functional level of independence that indivi-
duals may expect to have in adulthood and possible
health-related complications as individuals with this
deletion age.
Unresolved questions
Since 15q24 deletion syndrome is a relatively newly
described condition therea r es t i l lm a n yq u e s t i o n s
regarding the clinical manifestations that remain unan-
swered. Salient features that have been reported in a
minority of individuals, but have the potential to drasti-
cally affect prognosis and anticipatory guidance of indi-
v i d u a l sw i t ht h i sc o n d i t i o n ,a r et h eo c c u r r e n c eo f
neoplasias. At this time, it is unknown if there is a cau-
sal relationship between 15q24 deletion and the neopla-
sias described. Therefore, clinicians should be cognizant
of the possible risk of tumors in this population and
have low threshold for evaluation if neoplasia is remo-
tely suspected.
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male to female ratio of reported individuals remains
unknown. As previously mentioned, this may represent
an ascertainment bias rather than a true disparity. A
more balanced ratio would be expected as more indivi-
duals with 15q24 deletion syndrome are identified.
Lastly, the clinical and phenotypic consequence of the
reciprocal duplication of 15q24 remains unknown. Iden-
tification of more individuals with 15q24 duplication
will enable better classification of clinical features that
m a yb ea s s o c i a t e dw i t ht h ed uplication and a better
understanding of the molecular mechanisms that preci-
pitate both the 15q24 deletion and reciprocal
duplication.
Future prospects
Further characterization of the clinical phenotype, geno-
type-phenotype correlations, medical complications, and
developmental potential of individuals with 15q24 dele-
tion syndrome is imperative in order to fully compre-
hend the variability and severity of the syndrome.
Natural history studies and longitudinal follow-up by
the clinician will provide beneficial information on how
children, adolescents, and adults with 15q24 deletion
age and progress over time. This could lead to the
development of practical screening, management, and
surveillance guidelines for any individual diagnosed with
15q24 deletion syndrome.
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